Cinnagen Co · EPOR · Recombinant Proteins
erythropoietin beta is a recombinant proteins developed by Cinnagen Co. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or subcutaneous injection.
| Brand Names | CinnaPoietin ß, CinnaPoietin |
| Company | Cinnagen Co |
| Drug Class | Recombinant Proteins |
| Molecular Target | EPOR |
| Route | Injectable (Others), Intravenous (IV), Subcutaneous Injection |
| Status | Approved |
erythropoietin beta acts on 1 molecular target:
| EPOR | erythropoietin receptor (EPO-R) |
erythropoietin beta is developed for 2 unique indications across 1 therapeutic area.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Blood and lymphatic system disorders | Anaemia | ✓ Approved |
| Blood and lymphatic system disorders | Nephrogenic anaemia | ✓ Approved |
Zhygalova Zhygalova Ilona I, Blanco López Iago I, Dopazo Sotillo Silvia S, Carreira Sampayo Uxía U et al.
Morgan Rachel K RK, Matei Evelyn K EK, Pan Junru J, Ishikawa Tomoko T et al.
Developmental neurotoxicant exposures (e.g., lead [Pb]) are suspected contributors to dementia. Dementia is characterized by amyloid beta (Aβ) plaques and dysregulated metabolism. To better understand the relationship between environment and dementia risk, we assessed the impact of perinatal Pb exposure on dementia-related outcomes in the murine brain. Female mice were exposed to 32 ppm Pb or control water during gestation and lactation. Offspring were aged out to 3 weeks or 18 months. We measured Aβ in the 18-month cortex and performed untargeted metabolomics in plasma and cortex at 3 weeks and 18 months of age. Diffuse Aβ and Aβ-positive cells were significantly elevated with Pb exposure. Pb-associated metabolites were enriched for those implicated in oxidative stress, inflammation, and lipid metabolism. Pb was associated with molecular and metabolic features of dementia. Important biochemical classes provide insights into possible mechanisms by which developmental Pb exposure may contribute to dementia risk.
Ordoei Mahtab M, Behniafard Nasrin N, Namiranian Nasim N, Asadollahi Samira S et al.
T1DM is an autoimmune and chronic metabolic disorder characterized by the destruction of pancreatic beta cells. The Bacillus Calmette--Guérin (BCG) vaccine, originally used for tuberculosis prevention, has shown potential in modulating the immune response and improving beta-cell function. This study aimed to evaluate the therapeutic effects of two doses of BCG vaccine, administered four weeks apart, on glycemic control and selected immunological markers in patients with T1DM. In this single-center, double-blind randomized clinical trial, 33 patients with T1DM were enrolled and randomly assigned to intervention and control groups in a 1:1 ratio, matched by age and sex. The intervention group received two intradermal doses of the BCG vaccine, with a four-week interval. Fasting blood samples were collected at baseline and during follow-up to assess biochemical and immunological parameters. Patients were followed-up for 18 months. IRCT identifier: IRCT20201012049003N1; (date of registration: 2020/10/15). The mean age of participants was 11.25±3.32 years in the control group and 10.69±3.22 years in the BCG group. Anti-ICA levels significantly decreased in the BCG group by the end of the follow-up period. Although there was no significant difference in fasting blood glucose levels between the two groups, a significant reduction in HbA1c was observed in the BCG group after 18 months. The findings suggest that BCG vaccination may contribute to improved long-term glycemic control, as evidenced by reduced HbA1c levels, in patients with T1DM. Additionally, the decrease in Anti-ICA levels indicates a potential immunomodulatory effect, supporting the therapeutic promise of BCG in autoimmune diabetes.
Hutchings Brenna B, López-Legentil Susanna S, Stefaniak Lauren M LM, Nydam Marie L ML et al.
Ascidians are filter-feeding marine invertebrates that display inter- and intraspecific color variation and host diverse microbiomes. Although color variation has been used as an indicator of speciation and correlated with distinct microbiome structure in some colonial species, there is limited research on microbiome variation across color morphs and body regions in solitary ascidians. To address these knowledge gaps, three color morphs (purple, orange, and intermediate shades of pink) of the solitary Belizean ascidian Rhopalaea abdominalis were collected for phylogenetic analysis using the Cytochrome Oxidase I (COI) gene and for microbial characterization via sequencing the V4 region of the 16S rRNA gene. Microbial sequences derived from the ascidian branchial sac, gut, and tunic body regions were processed using both operational taxonomic unit (OTU) and amplicon sequence variant (ASV) pipelines to determine the resolution and consistency of sequence processing methods using mothur and QIIME 2 software, respectively. COI sequencing revealed two clades that were independent of color morphs. Microbiome characterization showed no significant differences in alpha- or beta-diversity across ascidian color morphs or COI clades but distinct microbiomes within each body region. The branchial sac harbored a higher number of core members (i.e., detected across all host individuals) that included known ascidian symbionts (e.g., Endozoicomonas), whereas the gut and tunic were colonized by taxa identified in seawater and across multiple classes of marine invertebrates. Results were highly congruent between OTU- and ASV-based pipelines, yielding statistically equivalent alpha-diversity metrics, consistent beta-diversity patterns, and similar core membership profiles. These findings reinforce the validity of both methods for studying microbial symbiont communities and corroborate previous research showing distinct microbiomes by body region and overall conservation when color morphs lack genetic differentiation.
Wu Xiaoyan X, Li Qiong Q, Cui Yi Y, Xu Nuo N
To investigate the intergroup differences in choroidal thickness (CT), choroidal vascularity index (CVI), and choroidal vascular volume (CVV) across non-autoimmune type 2 diabetes mellitus (T2DM) subtypes defined by beta-cell function and insulin resistance. This cross-sectional study enrolled 22 healthy controls (22 eyes) and 85 T2DM patients (85 eyes). T2DM patients were categorized into 4 groups using K-means clustering: Severe Insulin-deficient Diabetes (SIDD) =22, Severe Insulin-resistant Diabetes (SIRD)=26, Mild Obesity-related Diabetes (MOD)=16, and Mild Age-related Diabetes (MARD)=21. CT, CVI, CVV were measured by widefield swept-source optical coherence tomography angiography (WSS-OCTA) across three concentric annular regions(0 - 10 mm, 10 - 15 mm, and 15 - 20 mm), subdivided into 12 sectors. Linear mixed-effects and multivariate regression models were constructed to evaluate intergroup differences. Compared with the control group, both CT and CVV decreased significantly in most of the 12 analyzed regions across all T2DM groups, whereas the MOD and SIRD groups exhibited no statistically significant global changes. In contrast, CVI exhibited pronounced spatial and subtype-specific heterogeneity. In the SIDD group, CVI decreased in most regions, with significant reductions in the nasal sector of the 0 - 10 mm annulus (P<0.01]), and in the nasal and inferior sectors of the 10 - 15 mm annulus (P<0.01] and -0.065 (P<0.01). Conversely, the SIRD group demonstrated a widespread increase in CVI, with significant increased in the nasal (P < 0.05), superior (P < 0.05), and temporal (P < 0.05]) sectors of the 15 - 20 mm annulus. Compared with CT and CVV, CVI shows the highest spatial heterogeneity. This indicates that divergent metabolic drivers may exert opposing effects on choroidal vascular remodeling. This subtype-specific characterization enhances our understanding of diabetic choroidopathy pathophysiology and holds potential for guiding personalized screening and therapeutic strategies.
Abovich Arielle A, Fontana Marianna M, Claggett Brian B, Gillmore Julian D JD et al.
Vutrisiran, an RNA interference therapeutic, reduced all-cause mortality and recurrent cardiovascular events in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in the HELIOS-B trial. Whether concomitant disease-modifying or heart failure therapy modifies the efficacy of vutrisiran has not been described. We aimed to characterize patterns of concomitant therapy use in HELIOS-B, describe medication initiation rates by treatment arm, and evaluate whether concomitant therapy modified vutrisiran's treatment effect. In HELIOS-B, 654 randomized patients with ATTR-CM received vutrisiran or placebo. We assessed baseline use and postrandomization initiation of tafamidis, sodium-glucose cotransporter-2 (SGLT2) inhibitors, mineralocorticoid receptor antagonists (MRA), beta-blockers, and renin-angiotensin system inhibitors (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors), and used time-updated Lin-Wei-Yang-Ying models to evaluate treatment effect modification on the primary composite endpoint of all-cause mortality and recurrent cardiovascular events. At baseline, 40% of participants were receiving tafamidis and 77% at least 1 heart failure medication. MRAs and SGLT2 inhibitors were the most frequently initiated therapies during follow-up, with initiation rates numerically higher across all heart failure medication classes in the placebo group. There was no statistically significant evidence that the treatment effect of vutrisiran was modified by baseline or time-updated use of any medication class (P-interaction: tafamidis 0.95, SGLT2 inhibitors 0.59, MRA 0.92, beta-blockers 0.75, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor-neprilysin inhibitors 0.82). In HELIOS-B, there was no statistically significant evidence that the treatment benefit of vutrisiran on all-cause mortality and recurrent cardiovascular events was modified by concomitant use of tafamidis or heart failure therapies. These findings support the consistency of vutrisiran's efficacy across the spectrum of contemporary ATTR-CM pharmacotherapy. (HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy; NCT04153149).
+9996 more articles available with a free account
Sign up free to view all articles →